Page last updated: 2024-08-17

quinoxalines and Strabismus

quinoxalines has been researched along with Strabismus in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bailly, M; Cosgrave, E; Dahlmann-Noor, AH; Lowe, S; Vivian, AJ1
Gupta, A; Kekunnaya, R; Rao, HL; Sachdeva, V1
Han, SH; Hong, S; Kim, CY; Seong, GJ1

Trials

2 trial(s) available for quinoxalines and Strabismus

ArticleYear
Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery.
    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2009, Volume: 13, Issue:2

    Topics: Adrenergic alpha-Agonists; Adult; Blood Loss, Surgical; Brimonidine Tartrate; Clonidine; Combined Modality Therapy; Conjunctiva; Humans; Middle Aged; Pilot Projects; Prospective Studies; Quinoxalines; Strabismus; Vasoconstriction; Vasoconstrictor Agents

2009
Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults.
    American journal of ophthalmology, 2007, Volume: 144, Issue:3

    Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Brimonidine Tartrate; Conjunctival Diseases; Double-Blind Method; Eye Hemorrhage; Female; Humans; Hyaluronic Acid; Male; Oculomotor Muscles; Phenylephrine; Premedication; Quinoxalines; Strabismus

2007

Other Studies

1 other study(ies) available for quinoxalines and Strabismus

ArticleYear
Strabismus surgery hemostasis.
    Ophthalmology, 2012, Volume: 119, Issue:3

    Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Blood Loss, Surgical; Brimonidine Tartrate; Case-Control Studies; Female; Hemostasis, Surgical; Humans; Male; Oculomotor Muscles; Ophthalmic Solutions; Ophthalmologic Surgical Procedures; Phenylephrine; Postoperative Hemorrhage; Prospective Studies; Quinoxalines; Strabismus; Treatment Outcome; Vasoconstrictor Agents

2012